Alaunos Therapeutics - TCRT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.61
▼ -0.06 (-3.59%)

This chart shows the closing price for TCRT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alaunos Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCRT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCRT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Alaunos Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.61.

This chart shows the closing price for TCRT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Alaunos Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/16/2023HC WainwrightDowngradeBuy ➝ NeutralLow
8/15/2023LaidlawDowngradeBuy ➝ HoldLow
5/15/2023HC WainwrightUpgradeNeutral ➝ BuyLow
3/27/2023Wells Fargo & CompanyReiterated RatingOverweight$45.00Low
10/4/2022Wells Fargo & CompanyReiterated RatingOverweight$45.00Low
5/9/2022Cantor FitzgeraldReiterated RatingOverweightLow
5/4/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$45.00High
4/1/2022Cantor FitzgeraldReiterated RatingOverweightN/A
4/1/2022Raymond JamesSet TargetMarket Perform$30.00Medium
3/31/2022HC WainwrightReiterated RatingNeutralMedium
(Data available from 4/14/2019 forward)

News Sentiment Rating

-0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/17/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/16/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Alaunos Therapeutics logo
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.
Read More

Today's Range

Now: $1.61
Low: $1.55
High: $1.67

50 Day Range

MA: $1.87
Low: $1.40
High: $2.40

52 Week Range

Now: $1.61
Low: $0.66
High: $10.47

Volume

51,539 shs

Average Volume

60,172 shs

Market Capitalization

$25.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Alaunos Therapeutics?

The following equities research analysts have issued reports on Alaunos Therapeutics in the last year: HC Wainwright, and Laidlaw.
View the latest analyst ratings for TCRT.

What is the current price target for Alaunos Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Alaunos Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Alaunos Therapeutics in the next year.
View the latest price targets for TCRT.

What is the current consensus analyst rating for Alaunos Therapeutics?

Alaunos Therapeutics currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TCRT, but not buy more shares or sell existing shares.
View the latest ratings for TCRT.

What other companies compete with Alaunos Therapeutics?

How do I contact Alaunos Therapeutics' investor relations team?

Alaunos Therapeutics' physical mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The company's listed phone number is (346) 355-4099 and its investor relations email address is [email protected]. The official website for Alaunos Therapeutics is www.alaunos.com. Learn More about contacing Alaunos Therapeutics investor relations.